FIELD: immunology.
SUBSTANCE: invention relates to conjugates having interferon-γ activity. Claimed conjugate contains at least one non-polypeptide group, covalent bonded to IFNG polypeptide, wherein polypeptide contains amino acid sequence differ from starting IFNG polypeptide sequence by at least one added or deleted amino acid residue containing group to add non-polypeptide group.
EFFECT: therapy of diseases of improved effectiveness.
34 cl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VARIANTS OF GAMMA-INTERFERON POLYPEPTIDE | 2002 |
|
RU2296130C2 |
| MOLECULES SIMILAR TO FACTOR VII OR VIIA | 2001 |
|
RU2278123C2 |
| G-CSG CONJUGATES | 2001 |
|
RU2290411C2 |
| VERSIONS OF GLA DOMAIN OF FACTOR VII OR VIIa | 2004 |
|
RU2373282C2 |
| CONJUGATE OF FACTOR VII POLYPEPTIDE, METHOD OF OBTAINING IT, ITS APPLICATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | 2003 |
|
RU2362807C2 |
| CONJUGATE OF ANTIBODY AND DRUG, COMPOSITIONS BASED ON SAID CONJUGATE AND METHODS OF PRODUCING SAID CONJUGATE | 2015 |
|
RU2728235C2 |
| HOMOGENEOUS ANTIBODY AND DRUG CONJUGATES PRODUCED BY ENZYMATIC METHODS | 2015 |
|
RU2796266C2 |
| INTERLEUKIN 10 CONJUGATES AND OPTIONS FOR THEIR USE | 2019 |
|
RU2815891C2 |
| METHOD FOR PRODUCING PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX | 2012 |
|
RU2624129C2 |
| IL-15 CONJUGATES AND THEIR USES | 2019 |
|
RU2793754C2 |
